Companies Cryptocurrencies
Athenex Inc
Athenex Inc
Exchange: Nasdaq Global Select
IPO Date: 14/06/2017
CEO: Dr. Johnson Lau
Drug Manufacturers General Specialty & Generic Healthcare 🔗
  • ATNX
  • 0.471
  • 52671928
    market cap
  • -0.00260001
If you bought

shares of Athenex Inc (ATNX) on
You would have made
Old Price $12 Current Price $12

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 575 full-time employees. The firm’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The firm offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The firm’s Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

Address: 1001 Main St Ste 600 Buffalo NEW YORK 14203

Stay updated.